56 - Therapeutic Potential of Gastro-Gastric Fistulas Created via Lumen-Apposing Metal Stents for Nutritional Deficiencies in Roux-en-Y Gastric Bypass Patients: A Multicenter Study
65 - Efficacy and Safety of Icotrokinra, a Targeted Oral Peptide That Selectively Blocks IL-23 Receptor Activation, in Ulcerative Colitis: Results From Week 28 of ANTHEM-UC, a Phase 2b Dose-Ranging Trial
Location: North Ballroom 120BC
Presenting Author: Vipul Jairath, MBChB, DPhil, MRCP – Department of Medicine and Department of Epidemiology and Biostatistics, Western University
Oral Paper PresentationAnnual Scientific Meeting
8:40 AM - 8:50 AM MT
66 - Duvakitug, an anti-TL1a mAb, Demonstrates Efficacy and Favorable Safety as an Induction Treatment in Adults With Moderately to Severely Active Crohn’s Disease: Results From the RELIEVE UCCD Phase 2b Basket Trial
Location: North Ballroom 120BC
Presenting Author: Vipul Jairath, MBChB, DPhil, MRCP – Department of Medicine and Department of Epidemiology and Biostatistics, Western University
Oral Paper PresentationAnnual Scientific Meeting
8:50 AM - 9:00 AM MT
67 - Relationship Between Clinical and Histologic Findings With Tulisokibart Induction at Week 12 and Maintenance Dosing at Week 50 in the Phase 2 Randomized Controlled ARTEMIS-UC Study in Participants With Ulcerative Colitis
Location: North Ballroom 120BC
Presenting Author: Brigid S. Boland, MD – Altman Clinical Translational Research Institute, University of California, San Diego
Oral Paper PresentationAnnual Scientific Meeting
9:00 AM - 9:10 AM MT
68 - Guselkumab Maintenance Dose Regimens in Patients With High Disease Activity and Severity: Subgroup Analysis of Participants With Moderately to Severely Active Crohn’s Disease in the GALAXI Phase 3 Studies
69 - Clinical and Endoscopic Improvements With Risankizumab Treatment in Patients With Moderate-to-Severe Crohn’s Disease Who Previously Failed Ustekinumab
70 - Efficacy and Safety of Subcutaneous Guselkumab Rescue Therapy in Patients With Moderately to Severely Active Crohn’s Disease and Inadequate Response to Ustekinumab: Results From GALAXI 1, 2, & 3 Long-Term Extension
72 - Real World Outcomes of Upadacitinib Compared to Risankizumab as Second-Line Therapy in Patients With Crohn’s Disease Exposed to Tumor Necrosis Factor-Alpha Inhibitors
